MCID: LNG031
MIFTS: 51

Lung Benign Neoplasm

Categories: Cancer diseases, Respiratory diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lung Benign Neoplasm

MalaCards integrated aliases for Lung Benign Neoplasm:

Name: Lung Benign Neoplasm 11 14
Lung Neoplasms 43 71
Tumor of the Lung 11
Lung Tumor 53

Classifications:



External Ids:

Disease Ontology 11 DOID:3683
MeSH 43 D008175
NCIt 49 C3200
SNOMED-CT 68 126713003
UMLS 71 C0024121

Summaries for Lung Benign Neoplasm

MalaCards based summary: Lung Benign Neoplasm, also known as lung neoplasms, is related to lung adenoma and carcinoid syndrome, and has symptoms including hemoptysis An important gene associated with Lung Benign Neoplasm is NKX2-1 (NK2 Homeobox 1), and among its related pathways/superpathways are Overview of interferons-mediated signaling pathway and Malignant pleural mesothelioma. The drugs Midazolam and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include lung, lymph node and brain, and related phenotypes are Decreased viability and Reduced mammosphere formation

Related Diseases for Lung Benign Neoplasm

Diseases related to Lung Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 950)
# Related Disease Score Top Affiliating Genes
1 lung adenoma 31.7 TP53 SFTPC SCGB1A1 NKX2-1 KRAS HRAS
2 carcinoid syndrome 31.5 SYP ENO2 CHGA
3 carcinoid tumors, intestinal 31.5 SYP NKX2-1 ENO2 CHGA
4 inflammatory myofibroblastic tumor 31.4 TP53 MET EGFR
5 granular cell tumor 31.1 SYP NKX2-1 ENO2
6 pulmonary sclerosing hemangioma 30.8 TP53 SYP NKX2-1 CHGA
7 sclerosing hemangioma 30.7 TP53 SYP NKX2-1 CHGA
8 acinar cell carcinoma 30.6 SYP KRT7 CHGA
9 hemangioblastoma 30.5 SYP ENO2 EGFR
10 malignant peripheral nerve sheath tumor 30.5 TP53 MET KRT7 EGFR CDKN2A
11 benign mesothelioma 30.4 NKX2-1 KRT7 KRT20 CDKN2A
12 neuroendocrine tumor 30.4 SYP NKX2-1 NCAM1 KRT20 GRP ENO2
13 adenofibroma 30.4 TP53 KRT7 KRAS
14 sarcoma 30.4 TP53 MET KRAS HRAS ENO2
15 myoblastoma 30.4 SYP ENO2
16 oncocytoma 30.3 SYP KRT7 KRT20
17 tuberous sclerosis 30.3 TP53 SYP ENO2 CHGA
18 breast fibroadenoma 30.3 TP53 RASSF1 EGFR
19 bronchus cancer 30.3 KRT7 GRP FHIT ENO2 EGFR
20 islet cell tumor 30.2 SYP NCAM1 ENO2 CHGA
21 thymic carcinoma 30.2 SYP NKX2-1 KRT7 EGFR
22 myoma 30.2 TP53 KRAS ENO2 EGFR
23 laryngeal benign neoplasm 30.2 TP53 EGFR CDKN2A
24 squamous cell carcinoma 30.2 TP53 NKX2-1 KRT7 KRAS HRAS FHIT
25 pleomorphic adenoma 30.2 TP53 FHIT ENO2
26 rectum cancer 30.2 TP53 KRT20 KRAS HRAS EGFR
27 ewing sarcoma 30.2 TP53 SYP RASSF1 NCAM1 GRP ENO2
28 lung disease 30.2 SFTPC SCGB1A1 NKX2-1 GRP ENO2 CHGA
29 neurofibromatosis 30.1 TP53 KRAS HRAS EGFR CDKN2A
30 lung giant cell carcinoma 30.1 NKX2-1 KRT7 KRAS EGFR
31 alveoli adenoma 30.1 SFTPC SCGB1A1 NKX2-1
32 cystadenoma 30.1 SYP KRT7 KRT20 CHGA
33 mixed cell type cancer 30.1 TP53 SYP KRT7 KRAS HRAS ENO2
34 pleural disease 30.1 TP53 EGFR CDKN2A
35 ascending colon cancer 30.1 KRT7 KRAS HRAS
36 rectal benign neoplasm 30.1 TP53 KRT7 KRT20 KRAS HRAS EGFR
37 hemangioma 30.1 TP53 SYP NKX2-1 KRT7 KRAS ENO2
38 lung squamous cell carcinoma 30.0 TP53 RARB KRAS HRAS EGFR CDKN2A
39 exanthem 30.0 KRAS HRAS EGFR
40 transverse colon cancer 30.0 KRT20 KRAS HRAS
41 appendix adenocarcinoma 30.0 TP53 SYP KRT7 KRT20 KRAS HRAS
42 pleural cancer 30.0 TP53 EGFR CDKN2A
43 skin benign neoplasm 30.0 TP53 KRT7 KRT20 HRAS ENO2
44 adenocarcinoma in situ 30.0 TP53 NKX2-1 KRT7 KRAS HRAS EGFR
45 papillary adenocarcinoma 30.0 TP53 NKX2-1 KRT7 KRAS HRAS
46 sweat gland cancer 30.0 TP53 SYP KRT7 KRT20
47 lung oat cell carcinoma 30.0 TP53 SYP ENO2 CHGA
48 breast adenocarcinoma 30.0 TP53 KRT7 KRAS HRAS EGFR CDKN2A
49 pulmonary blastoma 30.0 TP53 SYP NKX2-1 KRAS EGFR CHGA
50 mucinous adenocarcinoma 30.0 TP53 NKX2-1 KRT7 KRT20 KRAS HRAS

Graphical network of the top 20 diseases related to Lung Benign Neoplasm:



Diseases related to Lung Benign Neoplasm

Symptoms & Phenotypes for Lung Benign Neoplasm

UMLS symptoms related to Lung Benign Neoplasm:


hemoptysis

GenomeRNAi Phenotypes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

25 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 CDKN2A CHGA EGFR ENO2 FHIT GRP
2 no effect GR00402-S-2 10.18 CDKN2A CHGA EGFR FHIT HRAS KRAS
3 Decreased viability GR00055-A-1 10.11 EGFR HRAS KRAS NCAM1
4 Decreased viability GR00055-A-2 10.11 EGFR HRAS KRAS
5 Decreased viability GR00055-A-3 10.11 KRAS
6 Decreased viability GR00106-A-0 10.11 KRAS
7 Decreased viability GR00221-A-1 10.11 EGFR HRAS KRAS
8 Decreased viability GR00221-A-2 10.11 HRAS KRAS
9 Decreased viability GR00221-A-3 10.11 HRAS
10 Decreased viability GR00221-A-4 10.11 EGFR
11 Decreased viability GR00301-A 10.11 KRAS
12 Decreased viability GR00381-A-1 10.11 KRAS
13 Reduced mammosphere formation GR00396-S 9.5 CHGA EGFR HRAS KRAS KRT7 NCAM1

MGI Mouse Phenotypes related to Lung Benign Neoplasm:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.32 CDKN2A CHGA EGFR ENO2 GRP HRAS
2 neoplasm MP:0002006 10.3 CDKN2A EGFR FHIT HRAS KRAS MET
3 homeostasis/metabolism MP:0005376 10.25 CDKN2A CHGA EGFR FHIT HRAS KRAS
4 normal MP:0002873 10.21 EGFR HRAS KRAS MET NKX2-1 RARB
5 no phenotypic analysis MP:0003012 10.19 CDKN2A CHGA EGFR HRAS KRAS MET
6 endocrine/exocrine gland MP:0005379 10.15 CDKN2A CHGA EGFR HRAS KRAS MET
7 renal/urinary system MP:0005367 10.11 CHGA EGFR HRAS KRAS KRT7 MET
8 muscle MP:0005369 10.03 CDKN2A CHGA EGFR HRAS KRAS MET
9 cellular MP:0005384 10.03 CDKN2A EGFR ENO2 KRAS KRT7 MET
10 digestive/alimentary MP:0005381 10.02 CDKN2A EGFR FHIT HRAS KRAS MET
11 cardiovascular system MP:0005385 9.93 CDKN2A CHGA EGFR GRP HRAS KRAS
12 respiratory system MP:0005388 9.77 CDKN2A EGFR ENO2 GRP HRAS KRAS
13 mortality/aging MP:0010768 9.5 CDKN2A CHGA EGFR FHIT HRAS KRAS

Drugs & Therapeutics for Lung Benign Neoplasm

Drugs for Lung Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 786)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
2
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
3
Ipratropium Approved, Experimental Phase 4 22254-24-6, 60205-81-4 657309 3746
4
Terbutaline Approved Phase 4 23031-25-6 5403
5
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
6
Reviparin Approved, Investigational Phase 4 9041-08-1
7
Remifentanil Approved Phase 4 132875-61-7 60815
8
Everolimus Approved Phase 4 159351-69-6 70789204 6442177
9
Alfentanil Approved, Illicit Phase 4 71195-58-9 51263
10
Acetylcysteine Approved, Investigational Phase 4 616-91-1 581 12035
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
13
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
14
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
15
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
16
Morphine Approved, Investigational Phase 4 57-27-2 5288826
17
Lactitol Approved, Investigational Phase 4 585-86-4 157355
18
Tropisetron Approved, Investigational Phase 4 105826-92-4, 89565-68-4 656665
19
Ondansetron Approved, Withdrawn Phase 4 99614-02-5 4595
20
Desflurane Approved Phase 4 57041-67-5 42113
21
Ketamine Approved, Vet_approved Phase 4 6740-88-1, 1867-66-9 3821
22
Cisatracurium Approved, Investigational Phase 4 96946-41-7 62887
23
Magnesium sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9
24
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
25
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
26
Clonidine Approved Phase 4 4205-91-8, 4205-90-7 2803 20179
27
Droperidol Approved, Vet_approved Phase 4 548-73-2 3168
28
Scopolamine Approved, Investigational Phase 4 51-34-3 153311 3000322
29
Olanzapine Approved, Investigational Phase 4 132539-06-1 135398745 4585
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
31
Acetaminophen Approved Phase 4 103-90-2 1983
32
Topotecan Approved, Investigational Phase 4 123948-87-8, 119413-54-6 60699 60700
33
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
34
Vemurafenib Approved Phase 4 918504-65-1 42611257
35
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 4112 126941
36
Ibandronate Approved, Investigational Phase 4 114084-78-5 60852
37
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
38
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
39 Epinephryl borate Phase 4
40 Pharmaceutical Solutions Phase 4
41 Endostar protein Phase 4
42 Calcium heparin Phase 4
43 Heparin, Low-Molecular-Weight Phase 4
44 Analgesics, Non-Narcotic Phase 4
45 Anti-Anxiety Agents Phase 4
46 GABA Modulators Phase 4
47 Fibrinolytic Agents Phase 4
48 Anticoagulants Phase 4
49 Sodium Channel Blockers Phase 4
50 Diuretics, Potassium Sparing Phase 4

Interventional clinical trials:

(show top 50) (show all 6131)
# Name Status NCT ID Phase Drugs
1 Randomised, Controlled Study Comparing Chemotherapy Plus Intercalated EGFR-Tyrosine Kinase Inhibitors Combination Therapy With EGFR-Tyrosine Kinase Inhibitors Alone Therapy as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Unknown status NCT02031601 Phase 4 Erlotinib;Gefitinib;Icotinib;Docetaxel;Pemetrexed;Platinum (cisplatin or carboplatin)
2 A Multicenter, Randomized, Open-label, Parallel-group Study of Paclitaxel Liposome and Cisplatin Compared With Gemcitabine and Cisplatin as First-line Therapy in Advanced Squamous Non-Small-Cell Lung Cancer Unknown status NCT02996214 Phase 4 Paclitaxel Liposome;Gemcitabine;Cisplatin
3 PET/CT and Roentgen in Lung Cancer. Evaluation of Patients in General Practice Unknown status NCT00675168 Phase 4
4 Clinical Study of First-line Treatment of Small Cell Lung Cancer (SCLC) With Anlotinib Hydrochloride in in Combination With EC/EP Unknown status NCT03890055 Phase 4 Anlotinib Hydrochloride
5 Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patients Who Have Not Progressed After 4 Cycles of Induction Chemotherapy of Pemetrexed in Combination With Platinum-based Regimen: A Prospective, Open, One-arm Clinical Study Unknown status NCT03792503 Phase 4 Apatinib;Pemetrexed
6 Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer: a Multi-center, Randomized, Open Label Study Unknown status NCT02348450 Phase 4 Irinotecan;Etoposide;Cisplatin
7 Efficacy of Nebulized Pulmicort Respules on Post Operation Pulmonary Complication During Pulmonary Single Lobectomy Surgery in Primary Lung Cancer Patients With COPD Unknown status NCT02504801 Phase 4 Budesonide
8 Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study Unknown status NCT02480634 Phase 4 Zoledronic acid
9 Randomized Open-label Study of the Impact of Prolonged Systemic Corticosteroid Therapy on the Course and Relapse Risk of Checkpoint Inhibitor Interstitial Lung Disease (Pneumonitis) Related to the Treatment of Solid Tumors With Anti-programmed-death Type 1 Receptor or Ligand Antibodies Unknown status NCT04036721 Phase 4 Prolonged glucocorticosteroid (prednisone) regimen;Short glucocorticosteroid (prednisone) regimen
10 Evaluation of the Efficacy of Domestic Gefitinib Tablets in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients Using a Multicenter, Randomized, Positive Drug Gefitinib Pharmacodynamics and Pharmacodynamics Unknown status NCT03264794 Phase 4 Gefitinib Tab (CTTQ),First medication;Gefitinib Tab (CTTQ),From the 8th day of trial;Gefitinib tablets (Yi Ruisha),First medication;Gefitinib Tab 250 MG(CTTQ),From the 8th day of trial.
11 Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research Unknown status NCT02513355 Phase 4 Changchun marina;cisplatin;Taxol;parapl
12 A Study of Endostar in Combination With Chemotherapy Followed by Endostar Maintenance Therapy in Patients With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) Unknown status NCT01028729 Phase 4 Endostar;Gemcitabine-Cisplatin chemotherapy
13 The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer Unknown status NCT02346318 Phase 4 Compound Kushen Injection
14 Safety Evaluation of Dexmedetomidine Monitored Anesthesia Care for Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Unknown status NCT01381627 Phase 4 Remifentanil;Dexmedetomidine
15 The Exploratory Clinical Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin (Endostar) for Local Advanced Non-small Cell Lung Cancer (NSCLC (Ⅲ A / Ⅲ B) ) Unknown status NCT01211002 Phase 4 radiotherapy / EP combined with recombinant human endostatin
16 A Randomized,Double-blind,Placebo-Controlled,Multicenter Clinical Trail of Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT02195453 Phase 4 Yangzhengxiaoji Capsule;Placebo Capsule
17 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
18 Maintenance Gemcitabine or Best Supportive Care for the Chinese Advanced NSCLC Patients Without Progression Disease After Given Four Cycles of the Induction Chemotherapy With Gemcitabine Plus Cisplatin Unknown status NCT01336192 Phase 4 Gemcitabine;Best supportive care
19 A Single Arm, Open Label, Perspective Study to Determine the Efficacy and Safety of Icotinib Combine Cryotherapy for Advanced NSCLC Patients Completed NCT02744664 Phase 4 Icotinib
20 Medical and Economic Evaluation of FORESEAL Versus the Current Therapeutic Approach (Stapling Alone or Associated With Tissue Sealant) in Terms of Air Leakage Duration After Lung Resection for Cancer. Completed NCT00925444 Phase 4
21 Conventional Versus Ultrasound-guided Transbronchial Needle Aspiration, Using Rapid On-site Cytological Evaluation, for the Diagnosis of Hilar/Mediastinal Enlarged Lymph Nodes: a Randomized Controlled Trial. Completed NCT01658280 Phase 4
22 "Red Morphine Drops" for Symptomatic Treatment of Dyspnoea in Terminal Patients With Primary Lung Cancer or Lung metastases-a Pilot Study Completed NCT00338481 Phase 4 Morphine p.o.;Morphine s.c.
23 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
24 Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer Completed NCT00451906 Phase 4 Platinum-based chemotherapy;Bevacizumab [Avastin]
25 A Placebo-Controlled, Multicentre, Randomised, Parallel Group, Trial to Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (StageIIIB/IV) Non Small Cell Lung Cancer (NSCLC) Chinese Patients Who HaveNot Experienced Disease Progression or Unacceptable Toxicity During Front Line Standard Platinum-Based Chemotherapy Completed NCT00770588 Phase 4 Gefitinib;Placebo
26 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
27 A Prospective, Multicenter, Phase-IV Clinical Trial to Assess Safety of Osimertinib in Indian Adult Patients With Metastatic Epidermal Growth Factor Receptor (EGFR) T790M Mutation-positive Non-small Cell Lung Cancer (NSCLC). Completed NCT03853551 Phase 4 Osimertinib
28 Volatile Anaesthesia and Perioperative Outcomes Related to Cancer (VAPOR-C): A Feasibility Study Completed NCT04074460 Phase 4 Propofol;isoflurane, sevoflurane or desflurane
29 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
30 A Study Of Cryospray Ablationtm Using Surgical Resection Specimens To Determine Safety And Histological Effect In The Lung Completed NCT00747773 Phase 4
31 Effect Of Ketamine Infusion On Oxygenation And Ventilation Mechanics In Patients With Chronic Obstructive Pulmonary Disease Applied One Lung Ventilation Completed NCT02962999 Phase 4 Ketamine;Saline
32 Anesthesia in Flexible Bronchoscopy for Lung Cancer Diagnostic Completed NCT00440960 Phase 4 propofol;midazolam;alfentanil;lidocaine
33 Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer Completed NCT00686322 Phase 4 Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
34 Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients Completed NCT02275702 Phase 4 Dexamethasone IV;Saline solution
35 Open-Label Single-Arm Phase IV Study of Pemetrexed in Taiwanese Patients With Advanced Non-Small Cell Lung Cancer Who Have Had Prior Chemotherapy Completed NCT00380718 Phase 4 pemetrexed
36 A Dual-Cohort, Prospective, Observational Study of Unresectable Stage IIIB/IV Non-Small Cell Lung Cancer Patients With and Without Bone Metastasis Completed NCT00099541 Phase 4 zoledronic acid
37 An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa Completed NCT01000740 Phase 4
38 Phase IV/II Open-label Study to Evaluate Prompt Response to Treatment With Cisplatin, Gemcitabine and Bevacizumab in Patients With Non-small Lung Cancer. Completed NCT02316327 Phase 4 gemcitabine, cisplatin and bevacizumab
39 ONCOXIN® and Quality of Life in Cancer Patients in a Real World Setting Study Completed NCT03550482 Phase 4
40 A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT01066884 Phase 4 erlotinib [Tarceva]
41 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
42 Individualized Pemetrexed Dosing in Patients With Non-small Cell Lung Cancer or Mesothelioma Based on Renal Function to Improve Treatment Response Completed NCT03655834 Phase 4 Pemetrexed
43 An Expanded Access Program of Tarceva (Erlotinib) in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Cancer Completed NCT00949910 Phase 4 Erlotinib
44 Multicenter Exploratory Trial of the Safety and Efficacy of Adjuvant Docetaxel and Carboplatin in Patients With Resected Non-small Cell Lung Cancer Completed NCT00883675 Phase 4 Docetaxel-Carboplatin
45 Clinical Study of Recombinant Human Endostatin Combined With NP Chemotherapy in the Treatment of Stage ⅢA Non Small Cell Lung Cancer Completed NCT02497118 Phase 4 Endostatin;Vinorelbine;Cisplatin
46 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
47 Safety of Low Dose Intravenous Contrast 64 Multi-Detector Computed Tomography Scanning in Patients With Chronic Kidney Disease Completed NCT02476526 Phase 4 Low Volume iso-osmolar non-ionic radio contrast medium;Acetylcysteine Inhalation;Sodium Bicarbonate Solution
48 Evaluation of the Usefulness of DurogesicD-TRANS for Pain Treatment in Lung Cancer Patients Completed NCT01060137 Phase 4 fentanyl matrix
49 Post-marketing Clinical Trial of Induction Chemotherapy of Pemetrexed Plus Carboplatin Followed by Pemetrexed Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer Completed NCT01020786 Phase 4 Pemetrexed;Carboplatin
50 A Multi-centre, Open-label, Phase IV, Interventional Study to Evaluate the Efficacy of Erlotinib (Tarceva®) Following 4 Cycles of Platinum-based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy Completed NCT01230710 Phase 4 Erlotinib

Search NIH Clinical Center for Lung Benign Neoplasm

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carboplatin
Carmustine
Cholecalciferol
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Etoposide
etoposide phosphate
Ifosfamide
Lomustine
Methotrexate
Methotrexate Sodium
Paclitaxel
Procarbazine
Procarbazine Hydrochloride
Teniposide
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: lung neoplasms

Genetic Tests for Lung Benign Neoplasm

Anatomical Context for Lung Benign Neoplasm

Organs/tissues related to Lung Benign Neoplasm:

MalaCards : Lung, Lymph Node, Brain, T Cells, Breast, Liver, Prostate

Publications for Lung Benign Neoplasm

Articles related to Lung Benign Neoplasm:

(show top 50) (show all 7767)
# Title Authors PMID Year
1
Effects of beta-carotene supplementation on molecular markers of lung carcinogenesis in male smokers. 53 62
20484175 2010
2
Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays. 53 62
20207772 2010
3
The neural cell adhesion molecule is involved in the metastatic capacity in a murine model of lung cancer. 53 62
20191608 2010
4
[A case of metastatic lung tumor with multiple ground glass opacities on chest CT]. 53 62
20432971 2010
5
Fhit regulates invasion of lung tumor cells. 53 62
19935706 2010
6
The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. 53 62
19639960 2009
7
Analysis of p53 mutations in histologically normal lung tissues and lung tumors from non-small cell lung cancer patients. 53 62
19072763 2009
8
Potential increase in the prognostic value of p53 mutation by Pro72 allele in stage I non-small-cell lung cancer. 53 62
19434453 2009
9
Arsenic activates EGFR pathway signaling in the lung. 53 62
19168569 2009
10
EGFR and K-ras mutations along the spectrum of pulmonary epithelial tumors of the lung and elaboration of a combined clinicopathologic and molecular scoring system to predict clinical responsiveness to EGFR inhibitors. 53 62
19289583 2009
11
Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. 53 62
19088172 2009
12
Estrogen receptor beta functions through nongenomic mechanisms in lung cancer cells. 53 62
19106194 2009
13
Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. 53 62
19155297 2009
14
Differential diagnosis of pulmonary carcinoma following head and neck cancer by genetic analysis. 53 62
19188169 2009
15
Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice. 53 62
19440353 2009
16
Human telomerase reverse transcriptase activated by E6 oncoprotein is required for human papillomavirus-16/18-infected lung tumorigenesis. 53 62
19010833 2008
17
Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer. 53 62
18651255 2008
18
Prostacyclin prevents murine lung cancer independent of the membrane receptor by activation of peroxisomal proliferator--activated receptor gamma. 53 62
19138979 2008
19
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. 53 62
18030469 2008
20
A Fra-1-dependent, matrix metalloproteinase driven EGFR activation promotes human lung epithelial cell motility and invasion. 53 62
18288638 2008
21
Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. 53 62
18645002 2008
22
Inhibitory role of focal adhesion kinase on anoikis in the lung cancer cell A549. 53 62
18343694 2008
23
Urocanic acid-modified chitosan-mediated PTEN delivery via aerosol suppressed lung tumorigenesis in K-ras(LA1) mice. 53 62
18292798 2008
24
Occurrence of mutations in the epidermal growth factor receptor gene in X-ray-induced rat lung tumors. 53 62
18271921 2008
25
Differential activity of caspase-3 regulates susceptibility of lung and breast tumor cell lines to Paclitaxel. 53 62
19238186 2008
26
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. 53 62
17889445 2007
27
Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas. 53 62
17927446 2007
28
p18Ink4c collaborates with Men1 to constrain lung stem cell expansion and suppress non-small-cell lung cancers. 53 62
17409423 2007
29
Phosphorylation of CBP by IKKalpha promotes cell growth by switching the binding preference of CBP from p53 to NF-kappaB. 53 62
17434128 2007
30
mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. 53 62
17235306 2007
31
Tumor-suppressive effects of MBP-1 in non-small cell lung cancer cells. 53 62
17178888 2006
32
Ganoderic acid T from Ganoderma lucidum mycelia induces mitochondria mediated apoptosis in lung cancer cells. 53 62
17007887 2006
33
Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. 53 62
17052260 2006
34
CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. 53 62
16708384 2006
35
Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer. 53 62
16876904 2006
36
Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells. 53 62
16934800 2006
37
Mutation and polymorphism in the EGFR-TK domain associated with lung cancer. 53 62
17409930 2006
38
Inhalation delivery and anti-tumor activity of celecoxib in human orthotopic non-small cell lung cancer xenograft model. 53 62
16902813 2006
39
Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T. 53 62
16928815 2006
40
Genetic and epigenetic alterations in lung tumors from bitransgenic Ki-rasG12C expressing mice. 53 62
16482519 2006
41
Chronic oral exposure to inorganic arsenate interferes with methylation status of p16INK4a and RASSF1A and induces lung cancer in A/J mice. 53 62
16543296 2006
42
Non-destructive micromethod for MRP1 functional assay in human lung tumor cells. 53 62
16374597 2006
43
Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model. 53 62
16144019 2006
44
A mouse model for tumor progression of lung cancer in ras and p53 transgenic mice. 53 62
16247444 2006
45
Anti-EphA2 antibodies decrease EphA2 protein levels in murine CT26 colorectal and human MDA-231 breast tumors but do not inhibit tumor growth. 53 62
16533422 2006
46
Advances in noninvasive pulmonary gene therapy. 53 62
16472094 2006
47
The differential effects of mutant p53 alleles on advanced murine lung cancer. 53 62
16288016 2005
48
Surfactant protein gene expressions for detection of lung carcinoma cells in peripheral blood. 53 62
16085219 2005
49
Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts. 53 62
15944764 2005
50
Histone deacetylation is directly involved in desilencing the expression of the catalytic subunit of telomerase in normal lung fibroblast. 53 62
16202213 2005

Variations for Lung Benign Neoplasm

Expression for Lung Benign Neoplasm

Search GEO for disease gene expression data for Lung Benign Neoplasm.

Pathways for Lung Benign Neoplasm

Pathways related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.52 TP53 RARB MET KRAS HRAS EGFR
2 12.49 TP53 RASSF1 MET HRAS EGFR CDKN2A
3
Show member pathways
12.39 TP53 KRAS HRAS EGFR
4
Show member pathways
12.36 TP53 KRAS HRAS EGFR
5 12.3 TP53 KRAS HRAS EGFR
6
Show member pathways
12.27 TP53 MET KRAS HRAS EGFR
7
Show member pathways
12.18 TP53 RASSF1 RARB KRAS HRAS FHIT
8
Show member pathways
12.09 TP53 MET KRAS HRAS EGFR
9 12.03 RASSF1 MET KRAS HRAS EGFR
10 12 TP53 MET KRAS EGFR
11 11.77 CDKN2A CHGA EGFR HRAS KRAS
12
Show member pathways
11.69 TP53 KRAS HRAS
13 11.53 KRAS HRAS EGFR
14 11.47 TP53 RASSF1 CDKN2A
15 11.44 MET HRAS EGFR
16 11.42 TP53 KRAS HRAS EGFR CDKN2A
17 11.39 EGFR HRAS KRAS
18 11.32 MET KRAS HRAS
19 11.29 MET HRAS EGFR
20 11.18 KRAS HRAS EGFR
21 11.15 TP53 KRAS HRAS EGFR
22
Show member pathways
11.1 EGFR HRAS KRAS
23 11.08 EGFR KRAS RASSF1
24 11 MET KRAS HRAS EGFR
25
Show member pathways
10.71 KRAS HRAS
26 10.7 TP53 RASSF1 KRAS HRAS EGFR CDKN2A

GO Terms for Lung Benign Neoplasm

Biological processes related to Lung Benign Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathway GO:1900738 9.46 GRP CHGA
2 regulation of long-term neuronal synaptic plasticity GO:0048169 9.43 SYP KRAS HRAS
3 Ras protein signal transduction GO:0007265 9.32 TP53 RASSF1 KRAS HRAS CDKN2A
4 positive regulation of miRNA maturation GO:1903800 9.26 TP53 EGFR

Sources for Lung Benign Neoplasm

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....